SARVESH RAJAN
Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism DU BOIS, PA NPI 1912915554
Browse related groups: Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism PA Madrigal Pharmaceuticals All categories
General Payments — all program years on this page
$4,418.62
- Category: General Payments
- Program years: PY2018–2024
- Record count: 242
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $1,038.82 across 46 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,038.82 | 46 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| Madrigal Pharmaceuticals | $166.09 | 2 |
| Amgen Inc. | $113.17 | 6 |
| Lilly USA, LLC | $113.03 | 6 |
| Novo Nordisk AS | $89.38 | 4 |
| SANOFI-AVENTIS U.S. LLC | $73.97 | 3 |
| DEXCOM, INC. | $54.33 | 3 |
| Xeris Pharmaceuticals, Inc. | $50.23 | 3 |
| Antares Pharma, Inc. | $41.35 | 2 |
| Abbott Laboratories | $37.64 | 2 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $35.83 | 2 |
| CHIESI USA, INC. | $26.15 | 1 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $24.90 | 1 |
| Tandem Diabetes Care, Inc. | $22.01 | 1 |
| IBSA Pharma Inc. | $21.53 | 1 |
| Medtronic, Inc. | $21.29 | 1 |
| Insulet Corporation | $21.27 | 1 |
| Neurocrine BioSciences, Inc. | $19.62 | 1 |
| Alexion Pharmaceuticals, Inc. | $19.47 | 1 |
| ABBVIE INC. | $19.38 | 1 |
| BETA BIONICS, INC. | $18.92 | 1 |
| Ultragenyx Pharmaceutical Inc. | $18.61 | 1 |
| Bayer HealthCare Pharmaceuticals Inc. | $17.31 | 1 |
| Currax Pharmaceuticals LLC | $13.34 | 1 |
By program year
Records — PY2024 (46)
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.